FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1491696531> ?p ?o ?g. }

• W1491696531 abstract "As increases in health care spending outpace economic growth, governments increasingly face tough choices. One significant cost driver is the influx of new technologies, particularly expensive drug therapies. In response, provincial governments are increasingly scrutinizing the costs and benefits of new drugs and determining that despite some therapeutic benefit, they are not sufficiently beneficial to receive public funding. These choices raise complex legal, economic, political, and ethical issues. This paper explores these issues as they pertain to Ontario's recent decision not to publicly fund three cancer drugs - Velcade, Alimta, and Zevalin. To be clear, although not considered sufficiently cost-effective to warrant public funding in Ontario these drugs are of some therapeutic benefit; indeed, a physician may strongly recommend one or more of these drugs to extend a patient's life by a few months. This is illustrated by the fact that the provinces of Quebec, Alberta and British Columbia have all elected to fund these drugs in their public hospitals. That they have chosen public funding, when Ontario has not, illustrates that no sharp distinctions can be drawn about what is medically necessary (and thus publicly funded) and what is not. Ontario's decision has resulted in pressure from patients who want to buy the drugs but have the drugs administered within public hospitals. For safety reasons, these drugs need to be provided in hospital-like settings. Patients who can afford to pay for the drug still find it difficult to access them because there is only one private cancer clinic in Ontario (downtown Toronto). The Ontario government is considering whether or not to allow private-pay drugs to be administered within public hospitals - so that people who can afford to pay for the drugs can access them more readily. We explore Ontario's dilemma in three parts. Firstly, we address how Ontario's statutory context permits or acts as a bar to the sale of drugs in public hospitals. Second, we discuss the myriad of policy concerns government faces in deciding whether to permit the sale of cancer drugs in public hospitals: fairness, equality, sustainability, compassion, safety, and the effects of such a policy on the public system. Finally, given the difficulty in safely obtaining these drugs in a private setting, we address whether the government could be compelled to allow patients access to privately purchased drugs in public hospitals via a successful challenge under s. 7 of the Canadian Charter of Rights and Freedoms." @default.
• W1491696531 created "2016-06-24" @default.
• W1491696531 creator A5020431427 @default.
• W1491696531 creator A5062741623 @default.
• W1491696531 date "2011-11-16" @default.
• W1491696531 modified "2023-09-26" @default.
• W1491696531 title "The Private Sale of Cancer Drugs in Ontario's Public Hospitals: Tough Issues at the Public/Private Interface in Health Care" @default.
• W1491696531 hasPublicationYear "2011" @default.
• W1491696531 type Work @default.
• W1491696531 sameAs 1491696531 @default.
• W1491696531 citedByCount "1" @default.
• W1491696531 crossrefType "posted-content" @default.
• W1491696531 hasAuthorship W1491696531A5020431427 @default.
• W1491696531 hasAuthorship W1491696531A5062741623 @default.
• W1491696531 hasConcept C100001284 @default.
• W1491696531 hasConcept C10138342 @default.
• W1491696531 hasConcept C138816342 @default.
• W1491696531 hasConcept C144133560 @default.
• W1491696531 hasConcept C159110408 @default.
• W1491696531 hasConcept C160735492 @default.
• W1491696531 hasConcept C162324750 @default.
• W1491696531 hasConcept C17744445 @default.
• W1491696531 hasConcept C199539241 @default.
• W1491696531 hasConcept C3116431 @default.
• W1491696531 hasConcept C39549134 @default.
• W1491696531 hasConcept C71924100 @default.
• W1491696531 hasConceptScore W1491696531C100001284 @default.
• W1491696531 hasConceptScore W1491696531C10138342 @default.
• W1491696531 hasConceptScore W1491696531C138816342 @default.
• W1491696531 hasConceptScore W1491696531C144133560 @default.
• W1491696531 hasConceptScore W1491696531C159110408 @default.
• W1491696531 hasConceptScore W1491696531C160735492 @default.
• W1491696531 hasConceptScore W1491696531C162324750 @default.
• W1491696531 hasConceptScore W1491696531C17744445 @default.
• W1491696531 hasConceptScore W1491696531C199539241 @default.
• W1491696531 hasConceptScore W1491696531C3116431 @default.
• W1491696531 hasConceptScore W1491696531C39549134 @default.
• W1491696531 hasConceptScore W1491696531C71924100 @default.
• W1491696531 hasLocation W14916965311 @default.
• W1491696531 hasOpenAccess W1491696531 @default.
• W1491696531 hasPrimaryLocation W14916965311 @default.
• W1491696531 hasRelatedWork W1568489814 @default.
• W1491696531 hasRelatedWork W1577302577 @default.
• W1491696531 hasRelatedWork W1605944529 @default.
• W1491696531 hasRelatedWork W1890704888 @default.
• W1491696531 hasRelatedWork W2033856125 @default.
• W1491696531 hasRelatedWork W2082484392 @default.
• W1491696531 hasRelatedWork W2087129382 @default.
• W1491696531 hasRelatedWork W2098264793 @default.
• W1491696531 hasRelatedWork W2098396153 @default.
• W1491696531 hasRelatedWork W2103201557 @default.
• W1491696531 hasRelatedWork W2138058634 @default.
• W1491696531 hasRelatedWork W2190569919 @default.
• W1491696531 hasRelatedWork W2402152061 @default.
• W1491696531 hasRelatedWork W2461321288 @default.
• W1491696531 hasRelatedWork W2992932733 @default.
• W1491696531 hasRelatedWork W3124077486 @default.
• W1491696531 hasRelatedWork W3125788429 @default.
• W1491696531 hasRelatedWork W3148143203 @default.
• W1491696531 hasRelatedWork W3161242992 @default.
• W1491696531 hasRelatedWork W3178571864 @default.
• W1491696531 isParatext "false" @default.
• W1491696531 isRetracted "false" @default.
• W1491696531 magId "1491696531" @default.
• W1491696531 workType "article" @default.